New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

August 2020

Palatin Technologies Participates In Canaccord Genuity’s 40th Annual Growth Conference

Press Releases / By

Aug 13, 2020, 16:12 ET CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity’s 40th Annual Growth Conference in a Fireside Chat today …

Palatin Technologies Participates In Canaccord Genuity’s 40th Annual Growth Conference Read More »

Palatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease

Press Releases / By

Data Anticipated Q4 2020 Aug 05, 2020, 07:30 ET CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced completion of enrollment of its Phase 2 study with …

Palatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease Read More »

Scroll to Top